A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
NCT04560998
Completed
This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes. Participants will either get semaglutide or placebo ("dummy") medicine - which treatment participants get is decided by chance. Semaglutide is a medicine for type 2 diabetes that can be prescribed by doctors in some countries. Participants will get the study medicine (semaglutide or placebo) in a pre-filled pen for... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/02/2025
Locations: Angel City Research, Inc., Los Angeles, California +121 locations
Conditions: Diabetes Mellitus, Type 2, Peripheral Arterial Disease
Register for Updates
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
NCT05891496
Active Not Recruiting
The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease. Semaglutide is a medicine that doctors can prescribe in some countries for the treatment of type 2 diabetes and excess body weight. This study will help us understand whether semaglutide can also be used for the treatment of Alzheimer's disease. The study will last for about 77 weeks. In the first 12 weeks of treatment, participant... Read More
Gender:
ALL
Ages:
Between 55 years and 75 years
Trial Updated:
01/02/2025
Locations: Banner Sun Health Research Institute, Sun City, Arizona +9 locations
Conditions: Alzheimers Disease
Register for Updates
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
NCT05649137
Completed
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Univ of Alabama Birmingham, Birmingham, Alabama +66 locations
Conditions: Obesity, Diabetes Mellitus, Type 2
Register for Updates
Semaglutide for Post-Smoking Cessation Weight Management
NCT06173778
Recruiting
This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/09/2024
Locations: The University of Texas at Austin, Austin, Texas +1 locations
Conditions: Obesity, Overweight, Cigarette Smoking
Register for Updates
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
NCT05822830
Completed
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2 Diabetes. The study will last around 74 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Cahaba Research, Birmingham, Alabama +31 locations
Conditions: Obesity, Overweight
Register for Updates
Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes
NCT05119179
Recruiting
This project uses both transcriptomic- and genomic-level data to identify mechanisms of individual responses to glucagon-like peptide-1 (GLP-1) in Mexican-Americans with prediabetes. The GLP-1 hormone is essential for glucose reduction, weight loss, cardiovascular risk reduction, and renal protection. Newly discovered mechanisms will illuminate causal links between disease genotype and phenotype, which may ultimately guide personalized therapeutic approaches for type 2 diabetes, prediabetes, obe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: UTHealth Clinical Research Unit (CRU) at UT Brownsville, Brownsville, Texas
Conditions: PreDiabetes
Register for Updates
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547
Active Not Recruiting
The purpose of this study is to learn how well efinopegdutide works compared to placebo in people who have non-alcoholic steatohepatitis (NASH). Researchers will also learn about the safety and benefit of efinopegdutide and how well people tolerate the medicine. The main goal of the study is to compare how many people taking efinopegdutide or placebo stop showing evidence of NASH without liver scarring getting worse.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
11/28/2024
Locations: The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 3, Chandler, Arizona +174 locations
Conditions: Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
Register for Updates
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
NCT06699329
Completed
The goal of this study is to learn what happens in a person's body over time when they take enlicitide decanoate and semaglutide alone or at the same time. Enlicitide decanoate is a new medicine that lowers the amount of cholesterol in a person's blood. Semaglutide is a drug used to treat type 2 diabetes. Researchers want to learn what happens to the amount of semaglutide and enlicitide decanoate in a person's blood when each drug is taken alone and when they are taken together.
Gender:
ALL
Ages:
Between 19 years and 55 years
Trial Updated:
11/19/2024
Locations: Celerion (Site 0001), Lincoln, Nebraska
Conditions: Healthy
Register for Updates
Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
NCT05819138
Recruiting
This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way.... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
11/15/2024
Locations: University of Colorado Anschutz Medical Campus, Aurora, Colorado +1 locations
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis
NCT05064735
Completed
This study will look at participants body weight from the start to the end of the study. It will also look at how much pain participants have in participants knee from the start to the end of the study and how this affects participants daily life. This is to compare the effect on body weight and pain in the knee in people taking semaglutide with people taking "dummy" medicine. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Pa... Read More
Gender:
ALL
Ages:
All
Trial Updated:
11/10/2024
Locations: Baptist Health System, Montgomery, Alabama +65 locations
Conditions: Obesity
Register for Updates
Prevention of Progression of Prediabetes, Obesity and CV Risk
NCT06446531
Recruiting
The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/15/2024
Locations: University of Texas Health Science Center at San Antonio, San Antonio, Texas
Conditions: Pre-Diabetes, Weight, Body, Cardiovascular Diseases
Register for Updates
A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose
NCT05689099
Completed
In this study, a known investigational medicine called 'semaglutide' will be tested in 2 drug concentrations of 0.68 milligram per milliliter (mg/mL) and 1.34 mg/mL. Both drug concentrations are tested for the treatment of type 2 diabetes. The U.S. Food and Drug Administration (FDA), has approved semaglutide in prefilled pen-injector form. Currently, the drug concentration of 1.34 mg/ml can be prescribed in some countries including U.S. The objective of the study is to compare the amount of inve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
10/13/2024
Locations: Altasciences Clinical LA, Inc., Cypress, California
Conditions: Diabetes Mellitus, Type 2, Healthy Participants
Register for Updates